Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Panacea Biotec Limited

NSE: PANACEABIOPharmaceuticals

Share price

₹344.50

-3.66% close of 8 Oct 2026

Market cap ₹2,067 CrP/E —

Business score

How strong the business is, in one number. The parts behind it are in Pro.

33

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹2,067 Cr

P/E ratio

—

P/B ratio

2.5

ROCE

-2.4%

ROE

-2.4%

Dividend yield

0.0%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹607.7552-week low ₹296.05

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 10.3% over the past year, and -2.0% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from -20.8% to -0.3% over the last four years.

Whether it grew faster than its sector

It grew -2.0% a year against a sector median of 13.1% — 15.1 percentage points slower.

Room to re-rate, or risk of de-rating

It has no earnings, so there is no price-to-earnings to compare.

Whether growth justifies the valuation

It has no earnings to weigh the price against.

Profit growthPrice per ₹1 profitPer 1% growth
Panacea Biotec Limited — this one21%/yr——
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7
Cipla10%/yr29.6×₹3.0
Dr Reddy's Laboratories-4%/yr30.8×—

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 121 of 130 on returns, 122 of 127 on growth, 122 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

It is losing money on the capital in the business, so there is no advantage to measure.

Whether its growth pays for itself

No — Over the last five years the business itself consumed ₹540 crore of cash before any plant spend. But only about 4 of every 100 rupees of profit it reported over 12 years arrived as cash — the rest is tied up. Its cash comes back more slowly than it used to: it went from being paid 229 days before it paid its own suppliers to waiting 51 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

4 of 8 checks clear · 50%

Latest result · Q4 FY26

What the last results showed. Whether management kept its word is in Pro.

Standalone revenue was ₹111.12 crore and the quarter ended with a ₹0.18 crore net loss.

Announced 20 Aug 2026 · Standalone · Audited

Revenue

₹111 Cr

Net profit

-₹0 Cr

EPS

₹-0.03

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹2,067 Cr
Prev close
₹344.50
52w High
₹647
52w Low
₹292
Enterprise value
₹2,017 Cr
Beta
1.1
Price CAGR 1y
-17.0%
Price CAGR 3y
28.0%
Price CAGR 5y
6.0%
Price CAGR 10y
13.0%

Ratios

Return on assets
-0.6%
PEG ratio
—
P/E ratio
—
P/B ratio
2.5
EV / EBITDA
921.0
Industry P/E
38.0
ROCE
-2.4%
ROCE 5y average
-5.4%
ROE
-2.4%
Debt / Equity
0.0
Interest coverage
-0.2
Dividend yield
0.0%
ROE 3y average
-4.0%
ROE last year
-2.0%

Annual P&L

Annual revenue
₹640 Cr
Annual profit
-₹7 Cr
Operating margin
-0.7%
Net profit margin
-1.1%
EBITDA margin
-0.8%
Sales growth 3y
11.6%
Sales growth 5y
0.5%
Profit growth 3y
21.0%
Profit growth 5y
13.0%
EPS
₹-0.9
Sales growth TTM
10.0%
Profit growth TTM
43.0%
Dividend payout
0.0%

Quarter P&L

Sales latest quarter
₹200 Cr
Profit latest quarter
₹2 Cr
YoY quarterly sales growth
19.7%
YoY quarterly profit growth
-44.4%
OPM latest quarter
2.8%

Balance Sheet

Book Value
₹139
Face Value
₹1.0
Total debt
₹24 Cr
Total cash
₹64 Cr
Borrowings
₹24 Cr
Reserves / Equity
138.2

Cash Flow

Operating cash flow
₹17 Cr
Free cash flow
-₹37 Cr
FCF yield
-2.1%
Net cash flow
-₹25 Cr

Shareholding

Promoter holding
72.5%
FII holding
2.3%
DII holding
2.3%
Public holding
23.0%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,766.4033.54,23,8190.902,901.26.015,299.910.520.5
Divi's Lab.9,499.0084.62,52,1690.31902.065.53,080.027.822.0
Torrent Pharma.4,634.7079.01,76,2890.81566.05.84,921.054.915.2
Zydus Lifesci.1,115.6022.91,11,2820.09990.2-35.18,017.022.021.1
Laurus Labs2,023.00100.01,09,3050.10362.1125.52,026.329.117.8
Cipla1,302.8529.41,05,2530.98785.6-39.27,119.32.315.5
Mankind Pharma2,423.9546.91,00,1200.04574.129.64,030.612.913.5
Panacea Biotec343.502,1040.002.2113.1199.619.7-2.4
Median416.7034.32,1320.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales129143151136116147163133167141165167200
Expenses140147151143130140156159168159153164194
Material Cost837347908174
Change in Inventories-392.5010-25-7.0627
Purchases of Stock-in-Trade7.452.011.912.382.670.77
Employee Cost494648414744
Other Expenses584552454148
Operating Profit-10-3.56-0.15-6.04-1477.96-27-1.18-18122.575.67
OPM %-7.98-2.49-0.10-4.43-124.754.87-20-0.71-137.111.542.84
Other Income3468.46146.547.426.3936179.105.055.266.98
Exceptional items (within Other Income)28112.702.772.712.74
Interest10.910.850.820.870.980.991.040.862.141.851.201.18
Depreciation9.489.319.118.818.738.688.988.428.398.348.457.887.90
Profit before tax13-7.78-1.65-2.12-174.764.38-0.046.56-196.49-1.253.57
Tax %166.5633-6.13-6.861.05-1.374,87540-2740-2038
Net Profit11-8.29-2.20-1.99-164.714.44-1.993.96-143.89-12.20
EPS in Rs1.79-1.35-0.37-0.32-2.580.780.74-0.310.66-2.270.650.080.38
Diluted EPS in Rs-0.310.66-2.270.650.080.38

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales687653544593457544625661460559559640673
Expenses643541505509591484548674558579584644670
Material Cost214290
Change in Inventories-22-19
Purchases of Stock-in-Trade7.608.97
Employee Cost173181
Other Expenses212183
Operating Profit441123984-1346077-13-98-20-25-52
OPM %617714-291112-2-21-3.50-4.40-0.700.30
Other Income2870628338-2191,68715462553626
Exceptional items (within Other Income)3620
Interest105127101101105174185181443.8866
Depreciation67736857544346443937353333
Profit before tax-99-19-67-6645-178-1461,449131.48-7.95-7-10
Tax %310-161517912636320110-3
Net Profit-108-21-56-7638-194-1481,078-34-1.51-8.72-7-9
EPS in Rs-17-2.98-8.89-126.15-32-24176-5.42-0.19-1.37-0.88-1.16
Diluted EPS in Rs-1.37-0.88
Dividend Payout %000000000000

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
-0%
5 years
0%
3 years
12%
TTM
10%

Compounded profit growth

10 years
5%
5 years
13%
3 years
21%
TTM
43%

Stock price CAGR

10 years
13%
5 years
6%
3 years
28%
1 year
-17%

Return on equity

10 years
—
5 years
-10%
3 years
-4%
Last year
-2%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital6666666666.136.136
Reserves449426350303344193-235871837836829829
Borrowings1,1111,1059949416467428203420212224
Other Liabilities364317440349379449587848407378433404
Minority Interest-4.17-5.96
Total Liabilities1,9301,8541,7891,5981,3761,3901,1781,7591,2711,2411,2901,262
Fixed Assets1,1441,0711,001949806657609622600582567576
CWIP15516130402324341742102128144
Investments1597756051340310
Other Assets6166147506025427035341,114615517592532
Total Assets1,9301,8541,7891,5981,3761,3901,1781,7591,2711,2411,2901,262

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity3791131118105-30107-108-422-0-2717
Cash from Investing Activity-3716-2655-6-35-481,2834301065-40
Cash from Financing Activity-1-117-107-164-10191-47-1,176-18-3-3-1
Net Cash Flow-1-10-29-22612-2-10735-25
Free Cash Flow3085107103100-2189-119-424-71-77-37

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days527995847146494548374742
Inventory Days404516770651173344311296292282391251
Days Payable272318607540572463440327256244413247
Cash Conversion Cycle184278259195-328-73-801483762546
Working Capital Days-12627-46-96-36393-43-229-5-26551
ROCE %0423-1655-6-10-4-5-2

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters747474737372727272727272
FIIs0.260.260.270.260.370.381.160.791.061.361.602.31
DIIs0.570.690.841.071.161.161.491.521.801.851.962.25
Public262525252626252525242423
No. of Shareholders48,87847,09146,24245,51339,98235,44633,59334,25633,59334,59732,62033,532

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year -21.4% (₹438.10 → ₹344.50)Brick size ₹14.94 (fixed)Bricks 62
₹300₹400₹500₹600₹345Dec '25Feb '26Apr '26Jun '26Aug '26Oct '26
Price moved up one brickPrice moved down one brickLast close ₹344.50 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

-50.03inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

35,98,695inr

2026-03-31

News

News and filings about Panacea Biotec Limited. Open one to see why it matters.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • APIs & intermediates (tacrolimus, mycophenolic acid, paclitaxel, gliclazide etc. for formulations)
  • packing materials (vials, stoppers, ampoules)
  • vaccine antigens (viral / bacterial / recombinant, cell-culture based)

Sells to

  • Gavi, the Vaccine Alliance · Pentavalent EasyFive vaccine for GAVI-designated countries (funder/alliance; UNICEF procur…
  • Global Polio Eradication Initiative (GPEI) / WHO · WHO pre-qualified oral polio vaccines (tOPV/mOPV/bOPV) supplied to 50+ countries
  • PAHO (Pan American Health Organization) · Easyfive-TT WHO pre-qualified fully-liquid Pentavalent vaccine (DTwP-HepB-Hib)
  • UNICEF · Easyfive-TT WHO pre-qualified fully-liquid Pentavalent vaccine (DTwP-HepB-Hib); also WHO P…

Buys from

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE922B01023

Business segments

  • Vaccines · 64%
  • Formulations · 36%

Plants

  • Panacea Biotec Baddi Drug Product / Vaccine Formulations Facility
  • Panacea Biotec Lalru Drug Substance & Formulations Facility

News impact

Big market events that reach Panacea Biotec Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

21 Sep 2020demerger₹0
19 Sep 2011unspecified₹0.75
16 Sep 2010unspecified₹0.25

Splits, bonuses & buybacks

  • daily-prices repair: 9 rows from NSE's archive (replace 1, delete 1, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Bulk & block deals

DateWhoBought / soldSharesPrice
9 Jun 2026MICROCURVES TRADING PRIVATE LIMITEDSELL9,65,723₹626.61
9 Jun 2026MICROCURVES TRADING PRIVATE LIMITEDBUY9,65,723₹626.42
9 Jun 2026JUNOMONETA FINSOL PRIVATE LIMITEDBUY5,66,807₹623.60
9 Jun 2026JUNOMONETA FINSOL PRIVATE LIMITEDSELL5,65,285₹624.00
9 Jun 2026NK SECURITIES RESEARCH PRIVATE LIMITEDBUY5,31,543₹624.46
9 Jun 2026NK SECURITIES RESEARCH PRIVATE LIMITEDSELL5,31,543₹624.66
9 Jun 2026HRTI PRIVATE LIMITEDBUY4,22,246₹617.87
9 Jun 2026DIPAN MEHTA COMMODITIES PRIVATE LIMITEDBUY4,20,933₹624.39
9 Jun 2026DIPAN MEHTA COMMODITIES PRIVATE LIMITEDSELL4,20,933₹625.17
9 Jun 2026HRTI PRIVATE LIMITEDSELL4,17,995₹618.84

Insider trades

DisclosedWhoTypeSharesValue ₹ Cr
25 Aug 2026Nosheen Sheikh · Employees Immediate RelativeSELL3,0000.12

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.